129 related articles for article (PubMed ID: 37028800)
1. Anaplastic Classic Kaposi Sarcoma: PD-L1 Expression and Response to Immunotherapy: A Case Report and Review of the Literature.
Lolli I; Valentini AM; Ricci AD; Armentano R
J Natl Compr Canc Netw; 2023 Apr; 21(5):442-448.e2. PubMed ID: 37028800
[TBL] [Abstract][Full Text] [Related]
2. Stage-related PD-L1 expression in Kaposi sarcoma tumor microenvironment.
Joest B; Kempf W; Berisha A; Peyk P; Tronnier M; Mitteldorf C
J Cutan Pathol; 2020 Oct; 47(10):888-895. PubMed ID: 32310306
[TBL] [Abstract][Full Text] [Related]
3. Expression of Programmed Cell Death Proteins in Kaposi Sarcoma and Cutaneous Angiosarcoma.
Gambichler T; Koim S; Wrobel M; Käfferlein HU; Brüning T; Stockfleth E; Becker JC; Lang K
J Immunother; 2020 Jun; 43(5):169-174. PubMed ID: 32224717
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma.
Genovese G; Venegoni L; Fanoni D; Tourlaki A; Brambilla L; Berti E
J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):e269-e271. PubMed ID: 30835883
[No Abstract] [Full Text] [Related]
5. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
6. Primary pulmonary histiocytic sarcoma with high PD-L1 expression benefited from immunotherapy: A case report and bioinformatic analysis.
Lin Y; Cao Q; Hong A; Liang X
Clin Respir J; 2024 Mar; 18(3):e13741. PubMed ID: 38450981
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic Kaposi's sarcoma: 5 cases of a rare and aggressive type of Kaposi's sarcoma.
Chapalain M; Goldman-Lévy G; Kramkimel N; Carlotti A; Franck N; Lheure C; Audard V; Avril MF; Marcelin AG; Damotte D; Terris B; Aractingi S; Dupin N
Ann Dermatol Venereol; 2018 Jan; 145(1):21-28. PubMed ID: 29290414
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Durable Complete Response After Combined Immunotherapy Following Resection of Primary Tumor in a Gallbladder Cancer Patient With Distant Metastatic Lymph Nodes of Favorable Immune-Microenvironment.
Yi B; Zhao Z; Dong H; Yuan L; Wu Y; Xu Y; Jiang X; Sun C; Wu D; Xiao Y
Front Immunol; 2022; 13():820566. PubMed ID: 35242133
[TBL] [Abstract][Full Text] [Related]
9. PD-1 and PD-L1 expression in Kaposi sarcoma: A comparative study according to the pathological stage and clinical characteristics.
Kim YJ; Jung CJ; Won CH; Chang SE; Lee MW; Choi JH; Lee WJ
J Cutan Pathol; 2021 Feb; 48(2):221-228. PubMed ID: 32779238
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
12. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
Babacan NA; Pina IB; Signorelli D; Prelaj A; Garassino MC; Tanvetyanon T
Clin Lung Cancer; 2020 Sep; 21(5):e456-e463. PubMed ID: 32265109
[TBL] [Abstract][Full Text] [Related]
13. An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma.
Hatashima A; Archambeau B; Armbruster H; Xu M; Shah M; Konda B; Lott Limbach A; Sukrithan V
Thyroid; 2022 Aug; 32(8):926-936. PubMed ID: 35583228
[No Abstract] [Full Text] [Related]
14. Anaplastic Kaposi's sarcoma: a study of eight patients.
Tourlaki A; Recalcati S; Boneschi V; Gaiani F; Colombo A; Mancuso R; Brambilla L
Eur J Dermatol; 2013; 23(3):382-6. PubMed ID: 23783037
[TBL] [Abstract][Full Text] [Related]
15. Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report.
Kroloff MJ; Holz JB; Stern O; Shepherd CJ; Morrow M; Kayitalire L; Wong DJ
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36202556
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
Iwafuchi H; Nakazawa A; Sekimizu M; Mori T; Osumi T; Iijima-Yamashita Y; Ohki K; Kiyokawa N; Fukano R; Saito AM; Horibe K; Kobayashi R;
Hum Pathol; 2021 Oct; 116():112-121. PubMed ID: 34363798
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
18. Classic Kaposi sarcoma in a patient of Miao ethnicity followed up for 7 years: a case report.
Zhou J; Shen X; Wang X; Xiao K; Cao Y; Jiang Y
J Med Case Rep; 2021 Apr; 15(1):179. PubMed ID: 33866974
[TBL] [Abstract][Full Text] [Related]
19. One hundred and five Kaposi sarcoma patients: a clinical study in Xinjiang, Northwest of China.
Wu XJ; Pu XM; Kang XJ; Halifu Y; An CX; Zhang DZ; Yakeya B; Mijit J
J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1545-52. PubMed ID: 25350316
[TBL] [Abstract][Full Text] [Related]
20. Update on classic Kaposi sarcoma therapy: new look at an old disease.
Di Lorenzo G
Crit Rev Oncol Hematol; 2008 Dec; 68(3):242-9. PubMed ID: 18657433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
